DoD Peer Reviewed Cancer Convergent Science Cancer Consortium Award
ID: 354994Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354994
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the DoD Peer Reviewed Cancer Convergent Science Cancer Consortium Award (CSCCA) for innovative cancer research initiatives. This grant aims to foster transdisciplinary collaborations among scientists, clinicians, and consumer advocates to address complex cancer challenges, requiring applicants to focus on at least three distinct cancer types and align their proposals with the overarching challenges of the FY24 Peer Reviewed Cancer Research Program (PRCRP). The initiative emphasizes the integration of diverse disciplines to enhance cancer prevention, diagnosis, treatment, and quality of life, particularly benefiting service members and their families. The estimated total program funding is $32 million, with a minimum budget of $20 million expected for successful proposals, and key deadlines include Pre-Application submissions by July 24, 2024, and Full Applications by October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524PRCRPCSCCA_GG_Mod.pdf
    The Department of Defense (DOD) is offering funding for the FY24 Peer Reviewed Cancer Research Program, specifically through the Convergent Science Cancer Consortium Award (CSCCA). This initiative seeks collaborative applications focused on significant cancer research that addresses at least three designated cancer types while also aligning with military health focus areas. Key submission deadlines include Pre-Application submissions by July 24, 2024, and Full Applications by October 15, 2024. The funding is aimed at improving cancer outcomes for service members, their families, and the broader public, with particular emphasis on advancing research in areas with gaps regarding early detection, prevention, and survivorship. A minimum budget of $20M is expected for successful proposals, with awards anticipated by September 2025. Eligible applicants include various organizations, both domestic and foreign, which can submit applications through two portals. The program underscores the importance of consumer advocate involvement and emphasizes a convergent science approach to overcome complex cancer challenges. The overarching aim is to promote innovative, transdisciplinary cancer research that ultimately enhances the quality of life for affected individuals and contributes to military readiness.
    HT942524PRCRPCSCCA_GG.pdf
    Similar Opportunities
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Staff Research Program
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Staff Research Program, aimed at fostering collaborative basic research between its scientific staff and institutions of higher education. The program seeks to enhance the professional competence of Army Research Office (ARO) scientists by engaging in hands-on research that advances knowledge in various scientific disciplines, including engineering, physical, life, and information sciences. This initiative is crucial for maintaining the integrity of ARO's mission while promoting innovative research aligned with Army interests. Interested applicants must submit proposals via Grants.gov by February 19, 2025, with no cost-sharing requirement, and can direct inquiries to William A. Creech at william.a.creech3.civ@mail.mil or by phone at 919-549-4387.
    US Army Combat Capabilities Development Command (DEVCOM) Indo-Pacific Fundamental Research Collaboration Opportunities
    Active
    USAF 347 Contracting Squadron
    The USAF 347 Contracting Squadron is offering a federal grant opportunity titled "US Army Combat Capabilities Development Command (DEVCOM) Indo-Pacific Fundamental Research Collaboration Opportunities." This initiative aims to foster the discovery, development, and integration of novel science and technologies specifically within the Indo-Pacific region, explicitly excluding engagements in the Continental United States. The funding, categorized under Science and Technology and other Research and Development, has an award ceiling of $9.5 million and a floor of $10,000, with an expected 51 awards to be made. Interested applicants can reach out to Mr. Kazuhito Urano or Mr. Joshua B. Grubb for further inquiries, and proposals must be submitted by August 30, 2027, as detailed on the System for Award Management (SAM) website.
    Tactical Behaviors for Autonomous Maneuver
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    US Army Combat Capabilities Development Command Broad Agency Announcement
    Active
    ACC APG - Natick
    The US Army Combat Capabilities Development Command (CCDC) is inviting proposals through its Broad Agency Announcement (BAA) for research and development funding, managed by the ACC APG - Natick. This opportunity allows unrestricted applicants to submit white papers and proposals for grants and assistance agreements, focusing on various areas of interest outlined in the BAA solicitation document. The initiative is crucial for advancing the capabilities of the Army, with an expected 50 awards to be made. Interested parties should note that the submission deadline is February 28, 2025, and can reach out to Shawn P. Haubner at shawn.p.haubner.civ@mail.mil or by phone at 508-206-2067 for further information.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Funding Opportunity Announcement (FOA) for Cancer Center Support Grants (CCSGs) aimed at supporting NCI-designated Cancer Centers under the P30 activity code. These grants are designed to foster excellence in cancer research by integrating diverse research activities and enhancing collaboration among institutions, with eligible applicants including various educational and community organizations. The CCSGs emphasize a transdisciplinary approach to cancer research, with funding amounts of up to $1.2 million for Basic Cancer Centers and $1.4 million for Clinical Cancer Centers per year, potentially extending over five years based on merit. Interested parties can find more information and application details at the NIH website, and inquiries can be directed to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV. The application deadline is set for October 12, 2121.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)," aimed at accelerating the development of evidence-based cancer interventions that address health disparities among diverse populations in the United States. This initiative will support research that tests the impact of cancer-related interventions on outcomes through a pragmatic trial design, structured in two phases: the UG3 phase for preparatory activities and intervention refinement, followed by the UH3 phase for conducting the trial. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with funding amounts capped at $500,000 for the UG3 phase and $750,000 for the UH3 phase. Interested parties should note that applications are due by November 17, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.